Last reviewed · How we verify
empirical vancomycin dosing
At a glance
| Generic name | empirical vancomycin dosing |
|---|---|
| Sponsor | Central South University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention (PHASE1)
- Continuous vs. Intermittent Infusion Vancomycin (PHASE4)
- Empirical ANtibiotic THErapy in Adults Hospitalised With Malaria
- Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model (PHASE4)
- Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry
- Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- empirical vancomycin dosing CI brief — competitive landscape report
- empirical vancomycin dosing updates RSS · CI watch RSS
- Central South University portfolio CI